Meftahi Nedra, Namouchi Amine, Mhenni Besma, Brandis Gerrit, Hughes Diarmaid, Mardassi Helmi
Unit of Typing & Genetics of Mycobacteria, Laboratory of Molecular Microbiology, Vaccinology, and Biotechnology Development, Institut Pasteur de Tunis, Université de Tunis El Manar, Tunis, Tunisia.
Department of Medical Biochemistry and Microbiology, Box 582 Biomedical Center, Uppsala University, Uppsala, Sweden.
J Antimicrob Chemother. 2016 Feb;71(2):324-32. doi: 10.1093/jac/dkv345. Epub 2015 Nov 3.
MDR Mycobacterium tuberculosis clinical strains that cause large outbreaks, particularly among HIV-negative patients, are likely to have undergone the most successful compensatory evolution. Hence, mutations secondary to the acquisition of drug resistance are worthy of consideration in these highly transmissible strains. Here, we assessed the role of a mutation within rpoB, rpoB V615M, secondary to the rifampicin resistance-conferring mutation rpoB S531L, which is associated with a major MDR tuberculosis outbreak strain that evolved in an HIV-negative context in northern Tunisia.
Using BCG as a model organism, we engineered strains harbouring either the rpoB S531L mutation alone or the double mutation rpoB S531L, V615M. Individual and competitive in vitro growth assays were performed in order to assess the relative fitness of each BCG mutant.
The rpoB V615M mutation was found to be invariably associated with rpoB S531L. Structural analysis mapped rpoB V615M to the same bridge helix region as rpoB compensatory mutations previously described in Salmonella. Compared with the rpoB single-mutant BCG, the double mutant displayed improved growth characteristics and fitness rates equivalent to WT BCG. Strikingly, the rpoB double mutation conferred high-level resistance to rifampicin.
Here, we demonstrated the fitness compensatory role of a mutation within rpoB, secondary to the rifampicin resistance mutation rpoB S531L, which is characteristic of an MDR M. tuberculosis major outbreak strain. The finding that this secondary mutation concomitantly increased the resistance level to rifampicin argues for its significant contribution to the successful transmission of the MDR-TB strain.
导致大规模疫情爆发的耐多药结核分枝杆菌临床菌株,尤其是在HIV阴性患者中引发疫情的菌株,很可能经历了最为成功的适应性进化。因此,在这些高传播性菌株中,获得耐药性后产生的继发性突变值得关注。在此,我们评估了rpoB基因内的一个突变(rpoB V615M)在赋予利福平耐药性的rpoB S531L突变之后所起的作用,rpoB S531L突变与在突尼斯北部HIV阴性环境中进化出的一株主要耐多药结核疫情菌株相关。
以卡介苗作为模式生物,构建单独携带rpoB S531L突变或同时携带rpoB S531L和V615M双突变的菌株。进行个体和竞争性体外生长试验,以评估每个卡介苗突变体的相对适应性。
发现rpoB V615M突变总是与rpoB S531L相关联。结构分析将rpoB V615M定位到与先前在沙门氏菌中描述的rpoB补偿性突变相同的桥螺旋区域。与rpoB单突变卡介苗相比,双突变体表现出改善的生长特性,其适应性水平与野生型卡介苗相当。引人注目的是,rpoB双突变赋予了对利福平的高水平耐药性。
在此,我们证明了在赋予利福平耐药性的rpoB S531L突变之后,rpoB基因内一个突变的适应性补偿作用,这是一株主要耐多药结核疫情菌株的特征。这一继发性突变同时提高了对利福平的耐药水平,这一发现表明它对耐多药结核菌株的成功传播有重大贡献。